In juvenile myoclonic epilepsy, data are limited on the genetic basis of networks promoting convulsions with diffuse polyspikes on electroencephalography (EEG) and the subtle microscopic brain dysplasia called microdysgenesis.
Variant Kinase in Juvenile Myoclonic Epilepsy J uvenile myoclonic epilepsy is the most common form of genetic generalized epilepsy and the most common cause of seizures among adolescents and young adults. 1, 2 The disorder is distinguished by the clinical features of myoclonus when the patient awakens from sleep after being sleep-deprived or exposed to alcohol and by a characteristic electroencephalographic (EEG) pattern of bursting, high-amplitude polyspikes, which may be elicited by photic stimulation. [1] [2] [3] [4] The disorder affects approximately 8.5 million persons worldwide [5] [6] [7] and is treatable with antiepileptic medications, which must often be administered for the patient's lifetime. 4, 6 Approximately 16 to 17% of patients have resistance to antiepileptic medications and have intermittent seizures despite treatment. [4] [5] [6] [7] Data are limited on the molecular pathology underlying the networks that promote grand mal myoclonic-tonic-clonic convulsions, 3 diffuse high-amplitude polyspikes on EEG, 4 and the subtle microscopic brain dysplasia (microdysgenesis) that occur in patients with juvenile myoclonic epilepsy. (Microdysgenesis is characterized by an increased number of displaced heterotopic neurons in the molecular layer of gray matter and in white matter. 8 ) A total of 22 chromosomal loci have been associated with susceptibility to juvenile myoclonic epilepsy. 9, 10 Of these loci, 7 house genes that, when variant, cause rare mendelian forms of juvenile myoclonic epilepsy. Of these genes, 6 encode subunits that make up ion channels; the seventh, EFHC1, encodes a calcium-binding protein with an EF-hand motif and three domains that have sequences homologous to Drosophila melanogaster domains. 10 In most patients with juvenile myoclonic epilepsy, there is no known cause. We investigated whether variants in the gene encoding intestinal-cell kinase (ICK) 11 and in genes located close to EFHC1 on chromosome 6p12 cause juvenile myoclonic epilepsy in Hispanic, European-American, and Japanese patients.
Me thods

Ascertainment of Families
Researchers at the GENESS (Genetic Epilepsies Studies) consortium sites (located in the United States, Mexico, Honduras, Brazil, and Japan) ascertained 334 families through a proband with genetic generalized epilepsy. These patients included 310 probands who had adolescent-onset, awakening myoclonic seizures and polyspike waves measuring 3.5 to 5 Hz or who had juvenile myoclonic epilepsy. 3, 4, 9, 10 
Discovering Variants Associated with Juvenile Myoclonic Epilepsy
The first step was to look for a variant that segregated with affected family members of a large pedigree with juvenile myoclonic epilepsy (Family A), which we found among the 334 families with genetic generalized epilepsy ( Table 1; and Fig. S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). We sequenced the exomes 12 of 4 affected family members (Patients 9, 25, 27, and 30) and two persons who married family members, who were considered to be controls. After observing the presence of a variant in each of the 4 affected members and not in the controls, we went back to Family A and performed bidirectional Sanger sequencing 13 in samples obtained from all 37 members, including spouses, to find out whether the same variant cosegregated with affected status.
The second step was to screen for more variants of the candidate epilepsy gene in the 334 families with genetic generalized epilepsy. We used DNA melting-curve analysis (an assessment of the dissociation characteristics of doublestranded DNA during heating) 14 and targeted real-time DNA sequencing, 15 followed by confirmation on Sanger sequencing. 13 
Proving Pathogenicity of Variants
The third step was to vet all discovered variants through the guidelines of the National Human Genome Research Institute 16 for investigating causality of sequence variants in human disease and the evidentiary criteria recommended by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP) for classifying variants as pathogenic or benign. 17 For each variant discovered in a patient with juvenile myoclonic epilepsy, we calculated Bayesian factor logarithm of the odds (LOD) scores for cosegregating variants, 18 unconditional exact tests and odds ratios for case-control associations, 19 and allele frequencies in the databases of the 1000 Genomes Project, 20 the Genome Aggregation Database (gnomAD), 21, 22 and the National Heart, Lung, and Blood Institute GO Exome Sequencing Project (ESP). 23 We also made theoretical
T h e ne w e ngl a nd jou r na l o f m e dicine predictions with respect to pathogenicity using algorithms that measure evolutionary conservation at the level of DNA base pairs and that calculate deleterious effects on encoded amino acids. 24 We observed allele frequencies of noncoding regions in the Kaviar Genomic Variant Database, 25 the Haplotype Reference Consortium, 26 and gnomAD. 21, 22 We tested variants for their ability to impair the function of the candidate epilepsy gene 27 and determined whether mice that are deficient in the candidate epilepsy gene had convulsions resembling those in patients with juvenile myoclonic epilepsy. 28 Additional details regarding the methods that were used are provided in the Supplementary Appendix.
R esult s
Linkage Analyses and DNA Sequencing
Two-point linkage analysis and fine mapping 29, 30 in the 37-member Family A with 12 living affected members across four generations confirmed significant linkage to chromosome 6p12.2 with a maximum LOD score of 3.35 for variant D6S257 and of 3.27 for variant D6S1573. (Table 1, and  Table S1 and Fig. S1 Figure S1 and Table S1 in the Supplementary Appendix. Blank cells indicate that the clinical phenotype was not present. † Among the affected members of Family A, Patients 4, 27, 29, and 33 were clinically asymptomatic with polyspike waves on electroencephalographic recording. We mapped reads of FASTQ files (a text-based format for storing both a biologic sequence and its corresponding quality scores) from the exomes of four affected members of Family A (Patients 9, 25, 27, and 30) and two unaffected spouses to a reference genome, GRCh37/hg19, and used the Genome Analysis Toolkit 32 to improve alignment quality and variant calling (Fig. S1 in the Supplementary Appendix). We filtered 165,642 singlenucleotide variants (SNVs) and 12,865 insertiondeletion variants (indels) from the proband of Family A with ANNOVAR (a software tool to functionally annotate genetic variants detected from diverse genomes), 33 which left 287 SNVs and 98 indels. On removing variants found in the exomes of the two unaffected spouses, three nonsynonymous SNVs remained for analysis. Variants in TGFBI and PKG2 lay outside the candidate 6p12.2 region. Only variant K305T (c.914A→C) in ICK was located at the chromosome 6p12.2 locus that we identified by linkage, fine mapping, and haplotype analysis [29] [30] [31] in Family A.
Sanger sequencing 13 then confirmed cosegregation of the K305T variant with each of the 12 affected members and 3 unaffected members. Of the affected family members, 3 had received a diagnosis of juvenile myoclonic epilepsy, 2 had myoclonic-tonic-clonic convulsions only, 2 had febrile convulsions plus childhood absence seizures or neonatal myoclonias, 1 had febrile convulsions only, and 4 had polyspikes on EEG and were clinically asymptomatic. These results genetically implicated K305T as an autosomal dominant, possibly disease-causing trait. 16, 17 
ICK Variants in Other Affected Families
Among the 334 index patients with genetic generalized epilepsy, including 310 probands with juvenile myoclonic epilepsy, we identified ICK variants in 24 of the 310 probands (8%), using DNA melting-curve analysis 14 and targeted realtime DNA sequencing, 15 followed by confirmation on Sanger sequencing. 13 All 24 probands had juvenile myoclonic epilepsy (Tables S2 and  S3 in the Supplementary Appendix). Of the 24 probands, 17 had mixed European and American Indian ancestry, 4 had European ancestry, and 3 had Japanese ancestry (Table S6A in the Supplementary Appendix). Table S3 lists 25 ICK variants because it includes R272Q, which had been reported in Amish infants with the endocrine-cerebro-osteodysplasia syndrome. Of the 24 patients with juvenile myoclonic epilepsy who had ICK variants, 9 had families with other affected members; in these nine families, we again observed the implicated ICK variant to cosegregate with affected status. Five other persons were singleton probands (Fig. S1 in the Supplementary Appendix). Three other pedigrees (Families N, O, and P) had nonsegregating ICK variants ( Fig. S4 in the Supplementary Appendix). Figure 1 shows the genomic structure of ICK and its encoded protein, 34, 35 along with the position and pathogenicity status of 11 variants. 16, 17 (A classification of each variant according to ACMG-AMP criteria 17 is provided in Tables S8,  S9 , and S10 in the Supplementary Appendix.) An expanded view of the region of chromosome 6p that was identical by descent in Family A, including genomic and gene structure and location of variants in ICK, 34, 35 is provided in Figure S5 in the Supplementary Appendix.
Coinheritance and Bayesian Factor LOD Scores
We used a Bayesian method 18 to evaluate the causality of variants. Only four of the families that we evaluated were sufficiently large (>2 members with epilepsy) to yield significant P values: Family A with K305T (c.914A→C), Family B with I102L (c.304A→C), and Family I with intron variant c.(−172)−966G→A (all with juvenile myoclonic epilepsy) (Fig. S1 in the Supplementary Appendix) and the Amish family with the endocrine-cerebro-osteodysplasia syndrome. 36 According to the guidelines of the National Human Genome Research Institute, 16 these Bayesian factor LOD scores 18 implicate ICK variants in causing juvenile myoclonic epilepsy in Families A, B, and I; the cosegregation in three unrelated families is rated as strong evidence by the ACMG-AMP criteria 17 that variant ICK is causal.
Case-Control Study
A total of 24 variants were tested by the unconditional exact test 19 of homogeneity (binomial model) or independence (multinomial model) with the use of gnomAD population alleles as controls. Of these 24 variants, 13 reached statistical significance and had an odds ratio exceed-T h e ne w e ngl a nd jou r na l o f m e dicine ing 5 for the risk of juvenile myoclonic epilepsy (Table S5 in the Supplementary Appendix). In these analyses, we again found strong evidence that ICK variants cause juvenile myoclonic epilepsy, according to the ACMG-AMP criteria. 17 
Minor Allele Frequencies
Of the 24 ICK variants found in family members with juvenile myoclonic epilepsy, 8 were absent and 12 were extremely rare in the ethnically matched population group in gnomAD. 21, 22 One other ICK variant (c.1745-73C→G, found in a Mexican patient with juvenile myoclonic epilepsy) is also extremely rare in American Indians but is a benign polymorphism in Africans. Thus, there are 21 ICK variants that are absent or extremely rare in the gnomAD in which the allele was found. These 21 ICK variants were found in 22 patients with juvenile myoclonic epilepsy out of 310 cases (7%). The presence of ICK variant Three variants (c.658A→G, c.304A→C, and c.1843G→A) that were found in Japanese patients are extremely rare in East Asians in gnomAD 21, 22 and absent in the 1000 Genomes Project. 20 Two exonic ICK variants, c.914A→C in Family A and c.1894C→T in a Japanese family, are absent in almost all populations of gnomAD except among East Asians and American Indians, among whom they are extremely rare (0.0006 for c.1894C→T among East Asians and 0.0012 for c.914A→C among American Indians). In the ESP database, 23 c.1894C→T was also extremely rare (<0.000077), as was c.1843G→A (Table S6A and S6B in the Supplementary Appendix). Allele frequencies of variants in noncoding regions of ICK in public databases 21, 22, 25, 26 are provided in Table S6 , and predictions of protein pathogenicity, evolutionary nucleotide conservation, splicing consensus, and microRNA binding 24 are provided in Table S7 .
Translation start S E R I N E / T H R E O N I N E P R O T E I N K I N A S E C A T A L Y T I C D O M A I N
Experimental Studies in Mice
ICK was discovered almost two decades ago. 11, 34, 35 The ICK protein phosphorylates the regulatoryassociated protein of the mechanistic target of rapamycin (mTOR) and thereby activates mTOR complex 1, 35 which in turn controls progression from the G1 phase of the cell cycle. 34 It also phosphorylates Scythe (BAT3), a reaper-binding nuclear protein that inhibits apoptosis and cell proliferation. 37 Because ICK lies 0.58 Mb away from EFHC1 in 6p12.2 (in cis), we asked whether ICK and EFHC1 share disease pathways and assessed the effects of ICK variants K220E, K305T, A615T, R632X, and R272Q on mitosis, neuroblast migration, and apoptosis during cerebral neocortex development. 27 In an analysis of extracts obtained from E14.5 cortexes of mice, we found Ick messenger RNA expression in the telencephalon, its various cortical regions, cortical plate, intermediate zone, and ventricular and subventricular zones on reverse-transcriptase-polymerase-chain-reaction assay ( Fig. 2A ) and in situ hybridization (Fig. 2B) .
We introduced constructs encoding wild-type or variant Ick proteins, tagged with enhanced green fluorescent protein (EGFP), and also a construct encoding EGFP on its own, into neural progenitor cells in mouse neocortex by ex vivo electroporation at E14.5. 27 Three days later, we examined the ventricular and subventricular zone, intermediate zone, and cortical plate and observed no significant mean (±SE) differences between brains transfected with EGFP alone (10.7±1.0%) and those transfected with EGFPtagged Ick (9.7±0.8%) (Fig. 3A and 3B ). In contrast, mouse brains transfected with variant Ick showed impaired radial migration. Fewer neurons reached the cortical plate and intermediate zone, with the exception of those transfected with the variant A615T. 27 In the mice transfected with EGFP-tagged variant Ick, there were more electroporated cells in the ventricular and subventricular zone than in mice transfected with EGFP-tagged Ick or EGFP alone. 27 The impaired migration of neural progenitor cells can be ex- 
-
T h e ne w e ngl a nd jou r na l o f m e dicine plained by haploinsufficiency or by a dominantnegative effect of ICK variants. 27 Our experiments in mice that were lacking a copy of Ick support the conclusion that such haplosufficiency impairs the migration of progenitor cells.
Because cortical progenitor proliferation, division, and cell-cycle exit (i.e., the point at which neuronal progenitor cells stop dividing, enter a quiescent resting state, become an immature neuron, and withdraw from the active cell cycle) are tightly coupled to neuronal migration, 34, 37 we studied the influence of Ick variants on mitotic progression and cell-cycle exit of cortical progenitor cells. Two days after ex vivo electroporation at E14.5, we stained sections of electroporated brain using an antibody against phosphohistone H3, an M-phase marker for mitotic progression (Fig. 3C) . 27 Cells that were electroporated with Ick variants had a significantly lower mitotic index than cells electroporated with wild-type Ick or EGFP (Fig. 3D) .
To better understand the effect of variant Ick on cell-cycle exit, we exposed brain slices to a short (1-hour) pulse of bromodeoxyuridine (BrdU) 24 hours after ex vivo electroporation. 27 We fixed brain slices 24 hours later. Triple immunolabeling with antibodies against GFP, BrdU, and Ki67 established the cell-cycle exit index (i.e., the percentage of progenitor cells exiting the cell cycle to become immature neurons in 24 hours) (Fig. 3E) . Cells that were electroporated with variant Ick had a significantly lower index than those electroporated with wild-type Ick or EGFP (Fig. 3F) .
Because Scythe, a physiologic substrate of Ick, inhibits apoptosis, 37 we analyzed apoptosis in brain slices 2 days after ex vivo electroporation at E14.5 using activated caspase-3 staining (Fig. 3G) . Overexpression of EGFP-Ick resulted in a significantly higher rate of apoptosis (18.8±0.8%) than EGFP (8.3±0.8%) (Fig. 3H) . Electroporation of Ick variants K220E, R272Q, K305T, and R632X (but not A615T) further increased apoptosis induced by wild-type protein.
27
Video and Electrocorticographic Monitoring of Mouse Model
We next investigated whether mice lacking a copy of Ick 38,39 model human juvenile myoclonic epilepsy. Because sleep that is induced by isoflurane is known to cause seizures in some mouse strains, 28 we videotaped mice that were heterozygous for Ick (i.e., carrying a single copy instead of two copies of the gene) and wild-type mice using an infrared camera while the mice were in a state of light sleep induced by 2% isoflurane. Tonic-clonic convulsions occurred significantly more often in mice that were heterozygous for Ick than in wild-type mice (P = 0.02 by Fisher's exact test) (see video). 28 One week later, we implanted intracranial electrodes over both somatosensory cortexes and electromyography electrodes into cervical muscles of mice that were heterozygous for Ick and wild-type mice, which were anesthetized with 2% isoflurane. One week later, we recorded electrocorticograms of freely moving heterozygous Ick mice and wild-type mice for 3 days. The freely moving heterozygous mice were the same mice that had previously had tonicclonic seizures during isoflurane anesthesia, whereas freely moving wild-type mice had not T h e ne w e ngl a nd jou r na l o f m e dicine had seizures. The heterozygous mice had more diffuse polyspike waves than the wild-type mice (P = 0.047) ( Fig. 4; and Fig. S8A , S8B, and S8C in the Supplementary Appendix). Diffuse polyspikes and high-frequency oscillations, which are known electrographic patterns of tonic-clonic convulsions, were recorded on the electrocorticograms. Brief diffuse polyspikes, the electrographic signature of myoclonias, were also recorded ( Fig. S8D in Supplementary Appendix).
Discussion
The data we obtained through the use of electroporated slices of mouse brain support the conclusion that pathogenic variants in ICK cause 7% of cases of juvenile myoclonic epilepsy by disrupting mitosis, neuroblast migration, and apoptosis. Pathogenic variants in ICK, similar to pathogenic variants in EFHC1, 10, 27 cause disease by impairing progenitor-cell migration, which manifests as microdysgenesis. 8 This process results in focal orbitofrontal cortical thickenings, as seen on voxel-based morphometry on magnetic resonance imaging. 10 The orbitofrontal cortical thickening could be a consequence of impaired apoptosis 10 or represent the cerebral cortical component of the cortical-subcortical network (i.e., consisting of the primary motor cortex, orbitofrontal cortex, caudate nucleus head, and cerebellum), which serve to promote myoclonic seizures and diffuse polyspikes on EEG (Fig. S9 in the Supplementary Appendix). However, the timing of disruption differs between these two genetic forms of juvenile myoclonic epilepsy. Pathogenic variants in ICK affect progenitor-cell proliferation, mitosis, and cell-cycle exit and so act at an earlier stage than pathogenic variants in EFHC1. 10 Pathogenic variants in EFHC1 and ICK share some similarities in expressed phenotypes. Homozygous ICK R272Q variants produce the fatal neonatal encephalopathy called the endocrinecerebro-osteodysplasia syndrome 36 ; the EFHC1 F229L variant, when homozygous, also produces a lethal epileptic encephalopathy of infancy. 40 Heterozygous pathogenic variants in ICK and EFHC1 can cause juvenile myoclonic epilepsy with myoclonic-tonic-clonic convulsions in patients who are otherwise neurologically normal. Three carriers in our study were entirely unaffected, as far as we could determine. These results suggest that some pathogenic variants in ICK have variable penetrance.
Of the 24 ICK variants that we detected in 310 patients with juvenile myoclonic epilepsy, 13 met the criteria for causality according to case association studies, whereas 21 were either absent or extremely rare in the gnomAD population in which the ICK allele was found. These significant genetic implications and associations were observed only in 24 patients with juvenile myoclonic epilepsy. None of the patients had photosensitivity, 4 a condition that would not be expected in patients of mixed European and American Indian ancestry with juvenile myoclonic we report striking variation with respect to epilepsy phenotypes both within and among families. Of 34 affected nonproband family members, 5 (15%) had juvenile myoclonic epilepsy, 10 (29%) had myoclonic-tonic-clonic seizures, 4 (12%) had pyknoleptic petit mal seizures alone or with myoclonic-tonic-clonic seizures, 4 (12%) had febrile seizures alone or with absence seizures or myoclonias, and 11 (32%) were clinically asymptomatic but had polyspikes or focal spikes on EEG. These results strongly suggest that ICK is pleiotropic (i.e., a single mutation has many different phenotypic consequences in a patient or among patients) and that epistatic loci with different genes are present in affected family members and interact with ICK and contribute to pleiotropism and clinical heterogeneity.
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